Leap Therapeutics Announces Study Update on Sirexatamab
Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology firm focused on immuno-oncology therapies, has released new data from the DeFianCe study regarding its lead compound, Sirexatamab (DKN-01), used in colorectal cancer treatment. The updated results emphasize significant improvements in progression-free survival (PFS) for certain patient populations, reinforcing Sirexatamab’s potential in oncology.
Key Findings from the DeFianCe Study
The pivotal DeFianCe study is designed to evaluate the efficacy of Sirexatamab, an anti-DKK1 monoclonal antibody, when combined with chemotherapy and bevacizumab compared to standard treatments. Recent analyses have shown promising results, particularly in patients categorized as DKK1-high, VEGF-naïve, and those with liver metastases. These subgroups exhibited noteworthy improvements in their cancer treatment outcomes.
Progression-Free Survival Results
As of the latest update in May 2025, patients receiving the Sirexatamab treatment demonstrated a median PFS of 9.2 months, compared to 8.31 months for the control arm. These findings suggest a notable hurdle in treatment efficacy, with statistical significance for patients in critical subgroups with high DKK1 levels showing even better results.
Overall Response Rates
The study also focused on overall response rates (ORR), which is crucial for assessing treatment effectiveness. The Sirexatamab arm reported a response rate of 35.1% by investigator assessment, with a positive trend observed. This points towards Sirexatamab's potential as a robust treatment option in challenging colorectal cancer cases.
Corporate Update and Strategic Review
In light of current market conditions, Leap Therapeutics announced it would streamline its operations, including a proposed workforce reduction aimed at enhancing financial sustainability. The board has initiated a process to explore various strategic alternatives to maximize shareholder value. This includes assessing potential partnerships or sales of Sirexatamab and another drug, FL-501, which is also in their pipeline.
Operational Changes and Financial Strategy
To ensure continued operations and effective capital management, Leap has projected to incur approximately $3.2 million in costs related to the workforce reduction over the next months. The company reported a healthy cash reserve amounting to approximately $32.7 million, which will support its ongoing initiatives and assist in navigating this transitional phase.
About Leap Therapeutics
Leap Therapeutics is committed to advancing targeted and immunotherapies that address significant unmet medical needs in oncology. The company's lead investigational product, Sirexatamab, is designed to target the DKK1 protein associated with colorectal cancer progression, while FL-501 is focused on the GDF-15 protein. Together, these therapies hold promise for improving patient outcomes.
Frequently Asked Questions
What recent results did Leap Therapeutics report on Sirexatamab?
Leap reported significant improvements in PFS and ORR among specific patient groups within its DeFianCe study, particularly for those with high DKK1 levels.
What is Sirexatamab?
Sirexatamab (DKN-01) is an innovative anti-DKK1 monoclonal antibody used in combination with standard chemotherapy for treating colorectal cancer.
What strategic alternatives is Leap Therapeutics considering?
Leap is exploring options such as partnerships, sales, and leveraging its cash reserves to maximize shareholder value.
How is Leap managing operational costs?
The company plans a significant workforce reduction and has estimated costs of around $3.2 million related to this initiative to preserve capital.
Where can I find more information about Leap Therapeutics?
Additional details about Leap and its ongoing projects can be found on their official website and public financial filings.
